107 related articles for article (PubMed ID: 8616077)
1. Levels of mdr1 and mrp mRNA in leukaemic cell populations from patients with acute myelocytic leukaemia are heterogenous and inversely correlated to cellular daunorubicin accumulation.
Xu D; Knaust E; Pisa P; Palucka K; Lundeberg J; Areström I; Peterson C; Gruber A
Br J Haematol; 1996 Mar; 92(4):847-54. PubMed ID: 8616077
[TBL] [Abstract][Full Text] [Related]
2. Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients.
Ross DD; Doyle LA; Schiffer CA; Lee EJ; Grant CE; Cole SP; Deeley RG; Yang W; Tong Y
Leukemia; 1996 Jan; 10(1):48-55. PubMed ID: 8558937
[TBL] [Abstract][Full Text] [Related]
3. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia.
Hart SM; Ganeshaguru K; Hoffbrand AV; Prentice HG; Mehta AB
Leukemia; 1994 Dec; 8(12):2163-8. PubMed ID: 7808005
[TBL] [Abstract][Full Text] [Related]
4. Multidrug resistance phenotype in leukaemic cells from patients with acute myelocytic leukaemia can be detected with 99Tc(m)-MIBI.
Gruber A; Areström I; Xu D; Liliemark J; Larsson SA; Jacobsson H
Br J Cancer; 1998 Jun; 77(11):1732-6. PubMed ID: 9667640
[TBL] [Abstract][Full Text] [Related]
5. Prolongation of medium exchange is associated with a decrease in function but not expression of the P-glycoprotein pump in leukaemic cells.
Hegewisch-Becker S; Faltz C; Hossfeld DK
Eur J Haematol; 1996; 56(1-2):12-22. PubMed ID: 8599988
[TBL] [Abstract][Full Text] [Related]
6. Different effects of metabolic inhibitors and cyclosporin A on daunorubicin transport in leukemia cells from patients with AML.
Knaust E; Porwit-MacDonald A; Gruber A; Xu D; Peterson C
Leuk Res; 2003 Feb; 27(2):183-91. PubMed ID: 12526924
[TBL] [Abstract][Full Text] [Related]
7. High levels of lung resistance related protein mRNA in leukaemic cells from patients with acute myelogenous leukaemia are associated with inferior response to chemotherapy and prior treatment with mitoxantrone.
Xu D; Areström I; Virtala R; Pisa P; Peterson C; Gruber A
Br J Haematol; 1999 Sep; 106(3):627-33. PubMed ID: 10468850
[TBL] [Abstract][Full Text] [Related]
8. Subcellular daunorubicin distribution and its relation to multidrug resistance phenotype in drug-resistant cell line SMMC-7721/R.
Yang JY; Luo HY; Lin QY; Liu ZM; Yan LN; Lin P; Zhang J; Lei S
World J Gastroenterol; 2002 Aug; 8(4):644-9. PubMed ID: 12174371
[TBL] [Abstract][Full Text] [Related]
9. Correlation of MDR1/P-170 expression with daunorubicin uptake and sensitivity of leukemic progenitors in acute myeloid leukemia.
Campos L; Guyotat D; Jaffar C; Solary E; Archimbaud E; Treille D
Eur J Haematol; 1992 May; 48(5):254-8. PubMed ID: 1353726
[TBL] [Abstract][Full Text] [Related]
10. Daunorubicin metabolism in leukemic cells isolated from patients with acute myeloid leukemia.
Bogason A; Masquelier M; Lafolie P; Skogastierna C; Paul C; Gruber A; Vitols S
Drug Metab Lett; 2010 Dec; 4(4):228-32. PubMed ID: 20670211
[TBL] [Abstract][Full Text] [Related]
11. Reversal of drug-resistance by cyclosporin-A in a patient with acute myelocytic leukaemia.
Sonneveld P; Nooter K
Br J Haematol; 1990 Jun; 75(2):208-11. PubMed ID: 2372507
[TBL] [Abstract][Full Text] [Related]
12. Isolation and characterization of daunorubicin-resistant AML-2 sublines.
Choi CH; Ling V
Mol Cells; 1997 Apr; 7(2):170-7. PubMed ID: 9163728
[TBL] [Abstract][Full Text] [Related]
13. Effects of verapamil on the cellular accumulation of daunorubicin in blast cells and on the chemosensitivity of leukaemic blast progenitors in acute myelogenous leukaemia.
Maruyama Y; Murohashi I; Nara N; Aoki N
Br J Haematol; 1989 Jul; 72(3):357-62. PubMed ID: 2765404
[TBL] [Abstract][Full Text] [Related]
14. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia.
Zhou DC; Zittoun R; Marie JP
Leukemia; 1995 Oct; 9(10):1661-6. PubMed ID: 7564506
[TBL] [Abstract][Full Text] [Related]
15. Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML.
Beck J; Handgretinger R; Klingebiel T; Dopfer R; Schaich M; Ehninger G; Niethammer D; Gekeler V
Leukemia; 1996 Mar; 10(3):426-33. PubMed ID: 8642857
[TBL] [Abstract][Full Text] [Related]
16. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinofuranosylcytosine sensitivity may predict clinical response in acute myeloid leukemia.
Schuurhuis GJ; Broxterman HJ; Ossenkoppele GJ; Baak JP; Eekman CA; Kuiper CM; Feller N; van Heijningen TH; Klumper E; Pieters R
Clin Cancer Res; 1995 Jan; 1(1):81-93. PubMed ID: 9815890
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of the mdr1 gene in blast cells from patients with acute myelocytic leukemia is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A.
Nooter K; Sonneveld P; Oostrum R; Herweijer H; Hagenbeek T; Valerio D
Int J Cancer; 1990 Feb; 45(2):263-8. PubMed ID: 1968051
[TBL] [Abstract][Full Text] [Related]
18. High mdr1- and mrp-, but low topoisomerase II alpha-gene expression in B-cell chronic lymphocytic leukaemias.
Beck J; Niethammer D; Gekeler V
Cancer Lett; 1994 Oct; 86(1):135-42. PubMed ID: 7954350
[TBL] [Abstract][Full Text] [Related]
19. MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Beck J; Niethammer D; Gekeler V
Leukemia; 1996 Jul; 10 Suppl 3():S39-S45. PubMed ID: 8656699
[TBL] [Abstract][Full Text] [Related]
20. Expression of mdr1, mrp, topoisomerase II alpha/beta, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias.
Beck J; Handgretinger R; Dopfer R; Klingebiel T; Niethammer D; Gekeler V
Br J Haematol; 1995 Feb; 89(2):356-63. PubMed ID: 7873386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
